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Abstract
Background: To raise the effectiveness of interventions, clinicians should evaluate important biopsychosocial
aspects of the patient’s situation. There is limited knowledge of which factors according to the International
Classification of Function, Disability, and Health (ICF) are most deviant between patients with knee osteoarthritis
(KOA) and healthy individuals. To assist in measures’ selection, we aimed to quantify the differences between
patients with KOA and healthy controls on various measures across the ICF dimensions of body function, activity,
and participation.
Methods: We performed an exploratory cross-sectional case-control study. In total, 28 patients with mild-to-
moderate KOA (mean age 61 years, 64% women) referred by general physicians to a hospital’s osteoarthritis-school,
and 31 healthy participants (mean age 55 years, 52% women), volunteered. We compared between-group
differences on 27 physical and self-reported measures derived from treatment guidelines, trial recommendations,
and trial/outcome reviews. Independent t-test, Chi-square, and Mann-Whitney U test evaluated the significance for
continuous parametric, dichotomous, and ordinal data, respectively. For parametric data, effect sizes were calculated
as Cohen’s d. For non-parametric data, ds were estimated by p-values and sample sizes according to statistical
formulas. Finally, all ds were ranked and interpreted after Hopkins’ scale. An age-adjusted sensitivity-analysis on
parametric data validated those conclusions.
Results: Very large differences between patients and controls were found on the Pain numeric rating scale1, the
Knee Injury and Osteoarthritis Scale (KOOS, all subscales)2, as well as the Örebro Musculoskeletal psychosocial scale3
(P < 0.0001). Large differences were found on the Timed 10-steps-up-and-down stair climb test4 and Accelerometer
registered vigorous-intensity physical activity in daily life5 (P < 0.001). Respectively, these measures clustered on ICF
as follows: 1body function, 2all three ICF-dimensions, 3body function and participation, 4activity, and 5participation.
Limitations: The limited sample excluded elderly patients with severe obesity.
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Conclusions: Very large differences across all ICF dimensions were indicated for the KOOS and Örebro
questionnaires together for patients aged 45–70 with KOA. Clinicians are suggested to use them as means of
selecting supplementary measures with appropriate discriminative characteristics and clear links to effective therapy.
Confirmative studies are needed to further validate these explorative and partly age-unadjusted conclusions.
Keywords: Osteoarthritis, knee, Muscle strength dynamometer, Physical fitness, Physical examination, Physical
activity, Exercise, Activities of daily living, International classification of functioning, disability, and health, Psychology,
Sociological factors
Background
Osteoarthritis is the second most prevalent condition of
all musculoskeletal and rheumatic diseases and the main
contributor to social activity limitations [1, 2]. Knee
osteoarthritis (KOA) has an incidence of 240 per 100,
000 person-years in adults, which is more than 2.5 times
higher compared to osteoarthritis of the hip [3].
Traditionally, KOA has been diagnosed by radiography
and arthroplasty considered to be the only effective treat-
ment [4]. Recent governmental-approved guidelines for pri-
mary care in Denmark and Sweden, however, state that a
KOA diagnosis can be made clinically and that the first-line
of care is physiotherapy-guided training and education [5].
This is supported through the diagnostic criteria provided
by the European League Against Rheumatism (EULAR),
developed specifically for primary care [6]. According to
EULAR, clinical examination alone can offer a confident
diagnosis of KOA. Other diagnostic criteria such as from
the American College of Rheumatology (ACR) [7], are pri-
marily developed for hospital care [6].
KOA has long been recognized as a whole organ disease
[4], but has more recently been explained as a whole person
chronic disease [4]. By the latter understanding, symptoms
and signs most often develop slowly over decades [8] and
can be manageable for most people through an early diag-
nosis and individualized strategies [4]. This new paradigm
requires a holistic view on diagnosis, clearly linked to self-
management aiming to improve the patient’s prognosis in
the long term.
In view of the International Classification of Function,
Disability, and Health [ICF] [9], which represents a systems
theory and biopsychosocial understanding [4, 10], the diag-
nostic criteria provided by EULAR and ACR offers limited
understanding of the overall clinical situation in patients
with KOA. In particular, the criteria do not consider the
ICF dimensions activity and participation. Furthermore,
similar limitations seem to apply to known risk and prog-
nostic factors documented in systematic reviews [11–13]
in which the predominant factors evaluated are sum-
marised mainly into body functions, personal, and disease-
related factors.
Acknowledging KOA as a whole person disease re-
quires a holistic and biopsychosocial approach. A proper
diagnostic assessment needs to include factors derived
across the ICF dimensions in order to pinpoint the most
important measures for empowering patients to self-
manage and cope with their most valued functional goals
[14, 15]. In a level 1 study of diagnostics, the relevant
question is to ask what assessments clearly differ be-
tween patients and healthy controls [16]. As indicated by
available diagnostic guidelines (EULAR, ACR), as well as
evidence from systematic reviews (referred above), that
discrimination question has gained little attention in
KOA viewed from an overall ICF perspective.
Thus, the main objective of the current study was to ex-
plore between-group differences in individuals with KOA
and healthy controls, by applying a battery of functional
measures derived from guidelines, trial recommendations
and previous systematic reviews [17–20] that captures a
spectrum of ICF dimensions. The second objective was to
examine the rank of these between-group differences (by
effect sizes) in order to pinpoint the most deviant func-
tions. The third objective was to analyse how these mea-
sures cluster on the ICF dimensions.
Methods
Design and ethics
We aimed to perform a cross-sectional, explorative,
matched case-control study. The study was approved by
the Regional Ethics Committee for Medical and Health
Research (REC 2016/984) and was conducted according
to the Helsinki declaration. All participants received oral
and written information and signed an informed consent
form before entering the study. Based on a moderate
effect size in knee extension strength between similar
groups, i.e. applying unpublished data from our lab re-
lated to an earlier study [21], our a priori sample size
calculation indicated that we required 20 participants in
each group, as the study was allocated 80% power to de-
tect an effect at p < 0.05 (cf. Statistics analysis). Although
we assumed that no adjustments were needed for mul-
tiple comparisons in exploratory studies [22–27], we still
aimed for 30 participants in each group. We recruited
individuals with KOA referred by general physicians
(GPs) to private physiotherapy clinics and to the osteo-
arthritis school at Trondheim University Hospital, from
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Nov 2016 to Dec 2017. In about the same period,
healthy volunteers were recruited via job visits, posters,
flyers, and electronic communication, from several dif-
ferent work places in the vicinity of the lab.
Data for each individual participant were collected
within a period of approximately 2 weeks through ques-
tionnaires and functional tests in the lab. The question-
naires were e-mailed as web-surveys together with the
informed consent forms through the Infopad system
[28]. The groups were aimed to be frequency-matched
[23] on age and gender through the eligibility criteria
below. The study was extensive as the questionnaires
took on average 40min and the physical functional test
protocol on average 2.7 h in the lab. (The current paper
presents data from a larger study.) At the very end of
the lab session, an accelerometer sensor was applied on
the anterior left thigh [29, 30] and worn for all hours
during 1 week, before it was returned by mail.
Participants eligibility
The inclusion criteria for patients were having KOA in the
tibiofemoral joint(s) diagnosed clinically (by GPs or phys-
iotherapists) and radiologically [31], main problem of pain
and limited physical function related to the knee(s), be
symptomatic for > 3months and daily in the last month,
understand Norwegian (orally and written), and be within
45–70 years old. Both genders were included. The upper
age-limit was sat to prevent possible confounding due to
between-group differences in (i) comorbidity [32] and (ii)
physical activity (due to retirement/freedom to reduce ac-
tivity according to KOA-symptoms), as well as an decline
in body function naturally exhibited at high age in both
groups [33].
The inclusion criteria for healthy volunteers were
aimed to be age and sex frequency-matched to the pa-
tients, and able to walk on even ground and negotiate
stairs without pain and having no knee complaints.
The exclusion criteria for all participants were surgery
to a lower extremity < 3 years ago, prior lower limb frac-
tures, generalized pain, pain from the spine, hips, or
ankles competing with that from the knee, body mass
index (BMI) > 35 [for repeatable optokinematic record-
ings [34] in the main study, data not reported here], and
medical diagnoses other than KOA with clear negative
influence on physical function and pain.
Measurements
The following health status constructs and instruments were
implemented, building on prior recommendations and evi-
dence [17–20] and sorted on ICF dimensions. That is, we
mainly applied recommended measures from the 2010
Dutch physiotherapy guideline for patients with knee and
hip osteoarthritis [17], the Osteoarthritis Research Society
International (ORASI) Clinical Trial Recommendations [18],
a systematic review on performance-based measures in
KOA [19], and measures applied in randomized controlled
trials (RCTs) reviewed according to the Cochrane Hand-
book [20]. Some instruments cross ICF dimensions and are
thus presented shortly under more than one ICF dimension.
Additional file 1 gives a detailed overview of the measure-
ment properties and scores-of-interpretation of all the ap-
plied instruments. Below we present them briefly.
Measures across all the ICF dimensions: body function,
activity, and participation
The Knee Injury and Osteoarthritis Outcome Scale
(KOOS), is a freely available knee-specific, self-reporting
outcome measure (SROM) for knee-related problems
[35]. It measures Pain, Symptoms, Activities in daily liv-
ing (ADL), Sport and recreation (Sports/Rec), and knee-
related quality of life (QoL) [36, 37]. The scores are
converted to percentages, 0 to 100, worst to best.
KOOS includes the Western Ontario and McMaster
Universities Osteoarthritis Index (WOMAC) 3.0 to en-
sure validity for older individuals.
Measures on the ICF body function dimension
On body function we used 14 measures. Four were
mainly performance-based: the Biodex System 4 dyna-
mometer [38, 39] [Biodex System Pro™, Biodex Medical
Systems, NY, USA] for knee extension strength (see
Procedures below); the six-minute walk distance test
[6MWT] [40] for aerobic endurance; the 30 s Chair to
Stand Test (n30sCST) [n = number of stands] [40] according
to Osteoarthritis Research Society International’s (OARSI)
video-descriptions [41] for fitness; and the Timed maximum
30 s single-leg stance [T30sSLS] [42] for balance.
Six were pure SROMs: the Numeric Pain Rating Scale
(NPRS) [43] for unidimensional pain; two custom-made
SROMs for Sleep problems and Vitality (Additional file 1);
the KOOS-Pain [44] and -Symptoms [44]; and Tampa
Scale of Kinesiophobia (TSK-13) [45] for fear of motion or
re-injury. Finally, four were SROMs post performance
tests [46]: Borg’s Rating of Perceived Exertion Category
Ratio 10 (RPE-CR10) and NPRS, both post the 6MWT
and the n30sCST.
Measures on the ICF activity dimension
We used nine measures on the activity dimension. Three
were performance-based: the Timed 10-step up-and-
down stair climb test [T10StUpDw] [47], the Timed up-
and-go [TUG] [40] for mobility, balance, walking ability,
and fall risk [35], and the 6MWT [47] for long-term
walking ability. Three SROMs: KOOS-ADL and -Sports/
Rec for activity problems, and the Patient specific func-
tional scale [PSFS] [48] for the three most problematic
activities. Finally, three measures were SROM: the NPRS
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given directly after the T10StUpDw, 6MWT, and the
TUG.
Measures on the ICF participation dimension
We used four measures on the participation dimension.
KOOS-QoL for knee-related quality of life [36, 37], the
European Health Interview Survey-Quality of Life 8-item
index [EUROHIS-QoL] [49] for generic QoL, the Örebro
Musculoskeletal Pain Screening Questionnaire 10-items
[OMSPQ-10] [50] for work and psychosocial factors,
and the AX3 3D accelerometer [3-axis logging acceler-
ometer, Axivity Ltd., Newcastle, UK] [29, 51] for time in
four intensities of physical activities in daily life (PADL).
Procedures
Before the lab-session, all participants filled out their re-
spective relevant SROMs. Only the patients, however,
registered PSFS and TSK-13. In the lab, within approxi-
mately 1 week after the questionnaires, we registered
participants’ characteristics, degree of radiographic KOA
(radiology reports), T30sSLS (on two force plates, Type
9260AA, Kistler, NY, USA), TUG, n30CST, 6MWT, and
T10-StUpDw. At the end of the lab session, we mea-
sured peak strength (detailed below).
Strength (peak torque) was recorded concentrically for
the quadriceps muscle at 60°/s of five maximal repetitions
applying the passive concentric isokinetic mode [52] of the
Biodex® System 4. The participants warmed up by the per-
formance tests 6MWT and 10StUpDw, and a set of 15 rep-
etitions at low-moderate load (in knee extension-flexion).
Strength tests were performed with 70° trunk inclination,
all starting with the right side before the left according to
the Biodex manual [52]. The passive mode was chosen due
to its feasibility in eccentric mode (data not reported here).
Fully passive recordings were taken in order to correct for
gravity (see Data processing). The system was calibrated
before each session. At the very end of the lab-session, an
accelerometer was fixed to the participants’ left thigh for
recording of PADL at 100Hz for 1 week.
Data processing
For T30sSLS data, the time on one leg from the force
plates was analyzed using a custom-made algorithm
based on inflections in MatLab (v. R2016a, MathWorks
Inc., USA). Participants stood with one leg on each
force plate and the time on one leg was recorded when
a foot left one of the plates. All outputs were validated
by inspecting the force graphs using Qualisys Track
Manager (QTM, Qualisys AB, Sweden), because the
algorithm was invalid for a few recordings where par-
ticipants stood on one leg already before the start of
data registration.
The AX3 accelerometer data was categorized into four
different intensities of PADL applying the OmGui Software
[53]. Additional file 1 describes the cut-points for the four
PADL-intensity levels.
For knee extensor strength, the passive torques were
added to the active ones in order to correct for the
limb’s own torque. This was done at the 30° knee-flexed
position (0° was the straight knee) in order to minimize
the passive length-tension influence. The result was cal-
culated as best of five repetitions divided by body weight
and reported at the 30° knee flexed position.
Process: recruitment change, age-mismatch, and
sensitivity analysis
Insufficient recruitment from primary physiotherapy care,
older patients (able to be) recruited from hospital care,
and low recruitment of older healthy volunteers, inflicted
a breach in the age-matching. The age-difference necessi-
tated an age-adjusted statistical sensitivity analysis of the
parametric data (cf. Statistics below).
Statistics analysis
Our sample size calculation assumed that no adjustments
were needed for multiple comparisons in an exploratory
study [22–27] and was performed in the recognized [54]
freeware G*Power version 3.1.9.1 [55–57]. This power
analysis was an a priori required sample size computation
based on t-test (the difference between two independent
means), with the following factors: Two tails, α error prob-
ability = 0.05, β error probability = 0.2 (i.e., power 1 - β =
0.8 or 80%), and a moderate effect sized [58] Cohen’s d =
0.914 for concentric isokinetic knee extension strength at
60°/s. This required 20 participants in each group. (Add-
itional output parameters were: noncentrality parameter
δ = 2.891, critical t = 2.024, degree of freedom = 38, total
sample-size 40, actual power = 0.804).
For continuous data, normality was inferred by histo-
gram inspections, quantile-quantile plots, and Kolmogorov-
Smirnov tests. For the equal variance assumption, Levene’s
test was performed. Then, for parametric data with no
significant outliers and equal variance, standardized mean
difference (SMD) by Cohen’s d was calculated with 95% CI.
Independent t-tests were also performed (SPSS v.24, IBM,
NY, USA). For continuous non-parametric data, we calcu-
lated median differences and 95% CI (StatsDirect v.2.8.0,
Statsdirect Ltd., Cambridge, UK). Then we tested the latter
data for differences between groups by medians using
Mann-Whitney U (SPSS), before the U statistics and sam-
ple size were used to point-estimate Cohen’s d applying
validated formulas [59, 60] at psychometrica.de [61].
Differences between groups on categorical variables
were compared by Chi-square test for gender and the
Mann-Whitney U test for education and sleep. Then,
point-estimates of Cohen’s d were calculated via χ2 and
U statistics, and sample sizes [59–61]. The alpha-level
was set to 0.05 for the two-sided tests [22, 24, 25].
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Data which pertained to both groups, were then com-
piled and ranked on point-estimates of SMD. The size of
the SMD was interpreted according to Hopkins [58] and
p-value values according to Rosner [62] (Additional file 1).
Due to the statistically significant age-difference (see Re-
sults), we performed a sensitivity analysis of co-variance
(ANCOVA) with age as the covariate on the parametric
data.
Qualitative analyses
For measures with at least moderate effect size, the clus-
tering on ICF dimensions of (i) body function, (ii) activity,
and (iii) participation were based on a content analysis
according to the ICF manual [9], definitions of activity as
“the ability to move around” [63], and of participation as
“the ability to perform daily activities” [64].
Results
Flow of participants and centres
Two participants were recruited in physiotherapy clinics,
without information on those who declined. At the hos-
pital, we recruited 26 patients out of 36 eligible, where
10 of those invited declined to participate motivated by
long traveling distances (n = 3), not interested (n = 4),
afraid of strength testing (n = 2), and too time-consuming
(n = 1). One participant answered the questionnaire but
withdrew from the study before the lab-test due to a flare-
up and was excluded from the analysis. Five individuals
did not qualify for participation due to old age (n = 3),
BMI, and an unstable heart. The 31 healthy control indi-
viduals who volunteered represented academic (n = 10),
administrative (n = 6), and health care personnel (n = 7).
Further, salespersons (n = 3), industry employees (n = 3),
and canteen staff (n = 2).
Participant characteristics
The patients with KOA were on average 6.4 years older.
There were no other significant differences on personal
factors. On average the patients had had pain for 11
years, had been diagnosed 10 years ago, and showed
mostly small-to-moderate radiographic KOA (Table 1).
Main results
The ANCOVA sensitivity analysis indicated only small
bi-directional changes in p-values after adjustment for
age (Table 2) Thus, we refer to the results of the main
analysis below.
Highly significant group differences and very large
effect sizes were found for (i) body function on Pain
last week, KOOS-Symptoms, and KOOS-Pain; for (ii)
activity on KOOS-Sport/Rec and KOOS-ADL; and for
(iii) participation on KOOS-QoL and Örebro. Table 3
shows the statistical details and Fig. 1 an overview of
the rated effect sizes.
Highly significant group differences and large effect
sizes were found for (i) body function post performance
on pain-10StepUpDw, pain-CS30s, and pain-6MWT; for
(ii) activity on 10StepUpDw; and for (iii) participation
on vigorous-intensity PADL (Fig. 1, Table 3).
Significant group differences and moderate effect sizes
were found for (i) body function on pain-TUG, knee exten-
sor strength on the involved leg, T30sSLS on the (most)
involved leg, and sleep problem; for (ii) activity on 6MWT
and TUG; and for (iii) participation on EUROHIS-QoL and
moderate-intensity PADL (Fig. 1, Table 3).
Clustering on ICF dimensions
For measures with at least moderate effect size, we display
the clustering on ICF dimensions in the left column of
Table 3 (largest to smallest effect size within each level).
However, some measures captured more than one dimen-
sion: The TUG mobility and 6MWT captured (i) the body
function and (ii) activity dimensions, the Örebro-psycho-
social (i) and (iii) the participation dimension, whereas the
KOOS and EUROHIS-QoL captured all dimensions (i-iii).
Discussion
Principle findings
The main objective of the current study was to explore
which recommended/applied measures that most clearly
distinguished patients with KOA from healthy controls
and describe which ICF dimension those would cluster
on. Across 27 measures, the current results indicated
that those from the disease specific KOOS (all subscales)
and the psychosocial-Örebro questionnaires demon-
strated the largest effect sizes for between-group differ-
ences, and that these measures together clustered across
climbing and the amount of time spent in vigorous-
intensity physical activity demonstrated the second largest
effect size. These clustered on the ICF dimensions activity
and participation, respectively. Finally, sleep problems,
knee extension strength, static one-leg balance, endurance
walking, and Timed up-and-go all showed moderate effect
sizes, where the three first clustered on the body function
dimension, and the two latter also clustered on the ICF
activity dimension.
Results discussion
ICF body function dimension and KOA
On the ICF body function dimension, our two measures
of pain and the KOOS-Symptom indicated very large
effect sizes. This is in accordance with findings from pa-
tients awaiting total knee replacement [65]. Further,
knee pain is the cardinal complaint in KOA and knee
symptoms are central in the diagnostic threes of EULAR
[6] and ACR [7]. The result of the current study high-
lights the importance of a proper baseline pain status, in
concordance with the importance of monitoring pain
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within and between strength exercise sessions shown in
methodologically and clinically strong RCTs [66–69].
According to recent systematically reviewed trial-evidence
[20, 69], pain monitoring is of high value within and be-
tween strength-training sessions indicated by the most
effective treatment protocols in RCTs also exhibiting high
methodological quality [66–69].
The current result indicated a medium between-group
difference on knee extension strength. This is compar-
able to the estimated effect sizes obtained in a meta-
analysis of previous cross-sectional case-control studies
[N = 6086] [70]. Thus, there is ample evidence for pa-
tients with KOA demonstrating moderate sized [58]
knee extensor weakness compared to healthy controls.
Table 1 Personal and health characteristics in the case- and control group
ICF Variables Cases
(n = 28)
Controls
(n = 31)
M or Med diff M or Med
d or WG
95% CI
Statistics
t, χ2, U
P-value
Personal factors Female, n (%) 18 (64) 16 (52) 379 (χ2) 0.3294
Age, yrs., M (SD) 61.7 (6.4) 55.3 (8.0) 6.4 2.6, 10.2 3.4 (t) 0.0014†
Height, m, M (SD) 1.72 (0.10) 1.73 (0.09) −0.02 −0.07, 0.03 − 0.7 (t) 0.517
Weight, kg, M (SD) 82.9 (12.7) 80.4 (16.6) 2.5 −5.2, 10.3 0.7 (t) 0.517
BMI, kg/m2, M (SD) 24.3 (3.5) 25.2 (5.1) 1.1 −1.1, 3.3 1.0 (t) 0.317
Education, n (%)
secondary school (10 yrs) 1 (4) 0 (0)
high school (13 yrs) 6 (21) 6 (19)
graduate (16 yrs) 14 (50) 13 (42)
post graduate (18 yrs. +) 7 (25) 12 (39) 368 (U) 0.281
Dominant leg (right, left, n) 26, 2 28, 3
Patients’ body function &
structure & activity factors
Yrs since diagnosis, M (SD) 10.2 (8.6) 6.9, 13.6
Yrs of knee pain, n (%)
1 yrs 2 (7)
1 to 3 yrs. 3 (11)
3 to 10 yrs 7 (25)
> 10 yrs 16 (57)
Affected knee (n, %)
One 14 (50)
Both 14 (50)
Pain medication (n, %)
None 15 (54)
Paracetamol 5 (18)
NSAIDs 5 (18)
Opoids 2 (7)
Others 1 (4)
TSK Fear of mov., M (SD) 24.4 (7.7) 21.4, 27.4
PSFS Activity 1, Med (IQR) 3.0 (5.0) 1.0, 5.0
Case-group only
X-ray grade (n knees, %) Inv. leg Uninv. leg
No X-rays taken 0 (0) 10 (36)
KL-grade II 9 (32) 9 (32)
KL-grade III 17 (61) 8 (29)
KL-grade IV 2 (7) 1 (4)
Notes. Case-group = patients with knee osteoarthritis; control-group = individuals without knee complaints; ICF = the International Classification of Function,
Disability, and Health of the WHO; M =mean; Med =median; diff = difference between groups; d = 95% difference between groups; WG = 95% difference within a
group; BMI = body mass index; NSAIDs = Non-Steroid Anti-Inflammatory Drugs; TSK = Tampa Scale of Kinesiophobia; mov. = movement/reinjury; PSFS = Patient-
Specific Functional Scale questionnaire; KL = Kellgren-Lawrence Grade, † = highly significant result
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Notwithstanding knee extension strength’s medium dis-
crimination, the therapeutic importance of knee extensor
strengthening is definitely supported by the Ottawa Panel’s
strongly recommended strength exercise programs (based
on a systematic review of RCTs) [69], wherein large effect
sizes [58] of treatment have been found for reducing pain
and improving function, in particular after three programs
of sitting or lying single-leg strength training [66–68].
These three strength programs showed roughly twice the
effect sizes [20, 71] of comparable recommended programs
[72], low risk of bias [20], and PEDro-score ≥ 6 of 10. Fur-
ther, their strengthening dose ([repetitions × resistance ×
sets]/muscle group) [73] was body-weight independent and
objectively recorded [74]. Most importantly though, they
coupled pain to dose-response, i.e. linked strength gain to
control on pain and objective strengthening dose. Specific-
ally, only these RCTs [66–68] monitored the 24 h load-pain
tolerance in a way similar to that explained for treatment of
patients with chronic patellar tendinopathy [75]. Fur-
ther underpinning the importance of pain vs. dose
control, OARSI recommends that strength-training
logs also include pain levels [76]. Thus, evidence indi-
cates that knee extensor strength has moderate dis-
crimination whereas the 24 h load-tolerance measure
shows a promising link to large effects on pain, func-
tion, and strength of strength exercise therapy.
Fig. 1 Relative difference among functional measures in patients with knee osteoarthritis compared to individuals without knee complaints. [Cf.
Table 3 and the Result section text for how these measures cluster on the ICF dimension(s)]
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The six-minute walk test captures important endur-
ance or long-term walking capability. A relevant ques-
tion is whether walking only 20 or 40m, as
recommended by ORASI [76], captures the same con-
struct. The present study, however, measured endurance
capacity through a six-minute walking test. Herein, the
differences between patients with KOA and controls
amounted to a moderate sized effect. Our finding is
comparable to data from two small-sampled case-
control studies on patients awaiting total knee replace-
ment [77, 78]. All these findings are, however, super-
seded by the large effect size in a much larger case-
control study of patients with moderate KOA (N = 146)
[79]. This contrast to the latter study is understandable,
though, given its 24% between-group difference in body
mass index (vs. our 3%, 13% [77], 12% [78]). In either
case, a meta-analysis of clinical trials has just indicated large
effects of aerobic endurance training on pain and physical
performance [as compared to usual care] [80], and another
such analysis indicated clinically relevant effects on physical
function of endurance walking applied as a sole interven-
tion [81]. Thus, evidence indicates at least moderate dis-
crimination of the six-minute walk test and that it offers
therapeutically important endurance information for effect-
ive endurance therapy in patients with KOA.
ICF activity dimension and KOA
Viewed from the activity dimension of ICF, the present
findings on KOOS-ADL and KOOS-Sports/Rec were in
concordance with the very large effect size seen in
patients awaiting total knee replacement [65] and people
with radiographic KOA [82] in case-control studies. Fur-
ther, in a recent meta-analysis of RCTs [80], strength
training and mind-body exercises exhibited the largest
therapeutic effects on KOOS-ADL and WOMAC phys-
ical function relative to other active therapies that were
also compared to standard care. Furthermore, a RCT
documented better outcomes when the intervention was
a similar (i.e., disease-specific) questionnaire used as a
checklist as compared to usual care [83]. Moreover, the
above-mentioned trial meta-analysis [80] also indicated
large therapeutic effects on pain and physical perform-
ance of intensive aerobic endurance exercises. Import-
antly, such exercises are captured in the problematic
activity of the KOOS-Sports/Rec. Thus, evidence indi-
cates important discrimination on KOOS-ADL and
KOOS-Sport/Rec, important outcome-measure value of
the KOOS-ADL, and finally, that the KOOS-Sports/Rec
needs further evaluation as an outcome measure in KOA.
The up-and-down stair climb test demonstrated a
large between-group difference in the current study.
This is comparable to the 160% longer average climbing-
time for patients with KOA in another similar study
[78]. However, the point-estimated effect size in the
latter only reached a moderate magnitude, as did the
finding in another large case-control study [79]. Indeed,
similar-numbered up-and-down stairs climb tests have
shown problems of both validity and reliability in mus-
culoskeletal [47] and KOA populations [40]. Increasing
and fixing the time of walking upwards to 20 s and
rather record the numbers of negotiated steps thus
seems like a promising alternative [40]. Further, stair ne-
gotiation as a sole exercise therapy has documented very
weak evidence and indeterminable outcomes in a sys-
tematic review of RCTs for patients with total knee re-
placement [84]. Thus, the evidence indicates medium
discrimination of a 10 stairs up-and-down climb test
with an uncertain connection to effective therapy.
ICF participation dimension and KOA
On the ICF participation dimension in the present study,
the KOOS Quality of life measure amounted to a very
large effect size, which is concurrent with that reported in
two previous case-control studies [78, 82]. Further, meta-
analyses of RCTs indicate important effects of exercise
therapy [85] and strength training [80] on health- and
knee-related quality of life. Therefore, evidence indicates
that the KOOS quality of life measure has very large dis-
criminative value and important outcome measure value
in effective trials for patients with KOA.
The current study found a very large between-group
difference on the Örebro-psychosocial measure. Surpris-
ingly, no previous case-control studies on KOA appear
to have used this questionnaire. Further, according to a
systematic review [86], therapy for psychosocial factors
might only be of limited additive importance for patients
with KOA because no significant effect of psychotherapy
on pain was documented. The latter is concurrent with
our patients’ mild score on kinesiophobia. For the indi-
vidual patient, however, those scoring above 60% on the
Örebro-psychosocial questionnaire have shown to be of
high risk for absenteeism [work/social activities] [87].
Therefore, more studies are needed to challenge the
present discriminative ability and evaluate the thera-
peutic relevance of the Örebro-psychosocial measure in
KOA.
When looking for relevant case-control studies to
compare the large between-group difference in vigorous-
intensity physical activity of the present study, we did
not find any. Interestingly though, when compared to
the 2018 American physical activity guideline for adults
[88] which recommends at least 75 min to 150 min of
vigorous-intensity aerobic physical activity a week, both
patients and controls were far from the target (average 0
vs 29 min). More relevant perhaps, the alternative of the
same guideline is 150 to 300 min of moderate-intensity
physical activity a week, whereupon our patients were
seemingly on the target (mean 286 min), although the
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variability amongst them was substantial (SD of 169min).
Our moderate between-group difference in moderate-
intensity physical activity, however, agreed with that re-
ported in two such previous studies [89, 90]. Thus, evidence
indicates that objectively obtained levels of moderate-
intensive physical activity have moderate discrimination
and obvious/inherent outcome measure value, but that its
therapeutic value needs evaluation in KOA.
Possible implications
For implications, the most important health measures are
those that offer important information on diagnosis/situ-
ational understanding, prognosis/therapy, and outcome-
evaluation, while being reasonably fast, easily applicable,
and low cost. Most of our measures with at least moderate
effect sizes might be applicable for such purposes [6, 91].
More importantly, in several case-control studies, the
KOOS has shown very large effect sizes on most factors
across all ICF dimensions. Although the KOOS is highly
discriminative, cost-free, and disease-specific [18, 35], it
does not collect frequency and intensity of activities in con-
trast to for example the generic University of California at
Los Angeles activity rating scale [92], the International
Physical Activity Questionnaire [93], and the Frenchay
Activities Index [35, 94]. For clinicians and researchers,
these complementary patient-reported measures are easily
available and cost-free [35] or available in web-based com-
puter systems at non-profitable costs (e.g. InfoPad [28] and
PROMIS [95]).
Importantly, because only some of the present measures
showed substantial discrimination and clear links to effect-
ive therapy, we hope the discussion-adjusted conclusions
[96] herein raise priority-concerns about which ones to
apply clinically or evaluate further in exploratory and con-
firmative studies [24].
Methods discussion
The current study has its limitations and strengths. On the
one hand, we did not manage to match the groups on age,
nor was it possible to adjust for its potential age-inflating
functional decline effects on the non-parametric data. Fur-
ther, the current sample size can be considered rather small
if one assumes that adjustments were needed for multiple
comparisons in this study according to classical statistical
texts [54, 97–100]. On the other hand, the age-adjusted
sensitivity analysis of the parametric data supported the un-
adjusted analysis. Further, both age-means were well within
the same clinical middle-aged maturation category (Mesh,
PubMed). Yet further, the Results discussion (of the current
study) revealed current results in general agreement with
those of optimally age-matched confirmative studies. More-
over, for the therein present “inflated” (stair climbing) or
“deflated” (endurance walking) results, true result variation
among samples [54, 97] is perfectly normal also among low
risk-of-bias studies (sifted in meta-analyses) [70]. Even fur-
ther, according to reputative statisticians, there was no need
[22–27], or inappropriate or even deleterious to sound stat-
istical inferences [22, 23, 27], to correct for multiple com-
parisons in the present exploratory study. Additionally,
according to the current sample size calculation and the 27
tests, the indicated number of false positive results (type I
errors) was 27 × 0.05 = 1.35 [24]. Or, just one of our signifi-
cant results was most certainly false. Should we thus have
adjusted for multiple comparisons? We believe not, because
the assumption of such adjustments is the “universal null
hypothesis” that holds random variation as the first-order
explanation, thus undercutting the premises that nature fol-
lows regular laws [22]. And because, in the present study,
making no such adjustments kept the statistical power high
and type II error-rate low [22, 27]. Concordantly, in the
present exploratory low-risk-measures’ study, we cared way
more about finding true differences than being afraid of
accepting a false positive finding. Thus, we infer reasonable
internal validity of this study.
The current study weighed its external validity against
important considerations. Small-sampled studies [e.g., n <
20] [54, 97] are known to increase the risk of chance in-
flated/deflated effects and thus decrease the generalizability
compared to large-sampled studies [e.g., n > 100] [54, 97],
whereas both too small or too large samples are unaccept-
able for clinical, methodological, and ethical reasons [101].
Comparingly, the current study’s sample-size was moderate
[e.g., n ≥ 20 ≤ 100] [54, 97], minimalized according to calcu-
lated requirements [with advantages on cost, feasibility, and
patients’ burden] [101], powered higher than comparable
exploratory studies [102, 103], and aligned with the as-
sumption of no need for adjustments of multiple compari-
sons in exploratory designs [22–27]. Admittingly, the
current study limited its generalizability to patients aged <
70 and with BMI < 35. The upper age-limit was sat mainly
due to the risk of higher comorbidity in the KOA-group at
higher ages [32], whereas the upper limit on BMI (including
WHO’s obesity class I, excluding class II-III) was sat to pre-
serve the repeatability of collected optoelectronic kinemat-
ics [34] (data not published here). Comparably, more than
3900 patients with KOA in over 50 Cochrane-reviewed
trials were dominated by the middle-aged and aged matur-
ation categories (45–70 years old) with a mean BMI ranging
25 to 32 [72]. Thus, even though an uncertainty remains
due to the partly unadjusted age-difference, the external
validity of our findings seems substantial. The largest
strength of the present study is to show the quantified rank
of a plethora of recommended and applied measures in
KOA [17–20] whereof only a minority showed considerable
between-group differences. The current findings presum-
ably prompt important priority concerns. However, such
concerns should at least be influenced by the effects of ther-
apy on these measures (cf. the Results discussion above).
Vårbakken et al. BMC Musculoskeletal Disorders          (2019) 20:462 Page 11 of 14
Conclusions
In conclusion, among 27 relevant measures, this present
study indicates very large differences across all ICF dimen-
sions for the Knee Injury and Osteoarthritis Outcome
Scale (KOOS) and the Örebro-psychosocial questionnaire
(OMSPQ-10) in patients aged 45–70 with mild to moder-
ate KOA in a primary/hospital care setting. Clinicians
might consider screening by these instruments as means
of selecting among relevant supplementary measures
demonstrating appropriate discriminative characteristics
and clear links to effective therapy. Confirmative studies
are needed to further validate these explorative and partly
age-unadjusted conclusions.
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